Endymed Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Endymed's earnings have been declining at an average annual rate of -15.1%, while the Medical Equipment industry saw earnings growing at 8.4% annually. Revenues have been growing at an average rate of 7.8% per year.
Anahtar bilgiler
-15.1%
Kazanç büyüme oranı
-15.2%
EPS büyüme oranı
| Medical Equipment Sektör Büyümesi | 15.2% |
| Gelir büyüme oranı | 7.8% |
| Özkaynak getirisi | -5.7% |
| Net Marj | -4.3% |
| Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Endymed Ltd's (TLV:ENDY) 25% Dip In Price Shows Sentiment Is Matching Revenues
Sep 23
Endymed Ltd (TLV:ENDY) Investors Are Less Pessimistic Than Expected
Aug 06Here's What's Concerning About Endymed's (TLV:ENDY) Returns On Capital
May 24Endymed Ltd's (TLV:ENDY) Share Price Not Quite Adding Up
Mar 11Endymed (TLV:ENDY) Is Looking To Continue Growing Its Returns On Capital
Oct 23We Like These Underlying Return On Capital Trends At Endymed (TLV:ENDY)
Jul 17Returns Are Gaining Momentum At Endymed (TLV:ENDY)
Apr 03Endymed's (TLV:ENDY) Returns On Capital Are Heading Higher
Nov 18We Like These Underlying Return On Capital Trends At Endymed (TLV:ENDY)
Jun 03Endymed (TLV:ENDY) Is Doing The Right Things To Multiply Its Share Price
Feb 13Here's Why We Think Endymed (TLV:ENDY) Is Well Worth Watching
Nov 28Endymed (TLV:ENDY) Is Experiencing Growth In Returns On Capital
Oct 31Is Now The Time To Put Endymed (TLV:ENDY) On Your Watchlist?
Aug 29Investors Will Want Endymed's (TLV:ENDY) Growth In ROCE To Persist
Aug 01We Like These Underlying Return On Capital Trends At Endymed (TLV:ENDY)
Apr 11Endymed Ltd's (TLV:ENDY) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Feb 15Returns On Capital - An Important Metric For Endymed (TLV:ENDY)
Jan 10Should You Use Endymed's (TLV:ENDY) Statutory Earnings To Analyse It?
Dec 14
Gelir ve Gider Dağılımı
Endymed nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 20 | -1 | 8 | 3 |
| 31 Mar 24 | 21 | 0 | 8 | 3 |
| 31 Dec 23 | 23 | 1 | 8 | 3 |
| 30 Sep 23 | 23 | 1 | 7 | 3 |
| 30 Jun 23 | 22 | 1 | 7 | 3 |
| 31 Mar 23 | 22 | 1 | 6 | 3 |
| 31 Dec 22 | 21 | 1 | 6 | 3 |
| 30 Sep 22 | 22 | 3 | 5 | 3 |
| 30 Jun 22 | 23 | 4 | 5 | 3 |
| 31 Mar 22 | 24 | 5 | 5 | 3 |
| 31 Dec 21 | 22 | 5 | 5 | 3 |
| 30 Sep 21 | 20 | 2 | 5 | 2 |
| 30 Jun 21 | 19 | 2 | 6 | 2 |
| 31 Mar 21 | 16 | 1 | 5 | 2 |
| 31 Dec 20 | 14 | 0 | 5 | 2 |
| 30 Sep 20 | 14 | 1 | 5 | 2 |
| 30 Jun 20 | 14 | 1 | 5 | 2 |
| 31 Mar 20 | 15 | 2 | 5 | 2 |
| 31 Dec 19 | 16 | 2 | 6 | 2 |
| 30 Sep 19 | 18 | 2 | 6 | 2 |
| 30 Jun 19 | 18 | 2 | 6 | 2 |
| 31 Mar 19 | 18 | 2 | 6 | 2 |
| 31 Dec 18 | 18 | 2 | 6 | 2 |
| 30 Sep 18 | 18 | 0 | 7 | 2 |
| 30 Jun 18 | 19 | -1 | 7 | 2 |
| 31 Mar 18 | 18 | -1 | 7 | 2 |
| 31 Dec 17 | 18 | -3 | 8 | 2 |
| 30 Sep 17 | 18 | -3 | 8 | 3 |
| 30 Jun 17 | 17 | -2 | 7 | 3 |
| 31 Mar 17 | 15 | -3 | 7 | 3 |
| 31 Dec 16 | 14 | -3 | 7 | 4 |
| 30 Sep 16 | 13 | -4 | 6 | 4 |
| 30 Jun 16 | 12 | -5 | 6 | 4 |
| 31 Mar 16 | 13 | -4 | 6 | 4 |
| 31 Dec 15 | 13 | -4 | 6 | 3 |
| 30 Sep 15 | 13 | -2 | 6 | 3 |
| 30 Jun 15 | 13 | 0 | 6 | 3 |
| 31 Mar 15 | 12 | 0 | 5 | 2 |
| 31 Dec 14 | 11 | 0 | 4 | 2 |
| 30 Sep 14 | 8 | 0 | 3 | 2 |
| 30 Jun 14 | 7 | -1 | 3 | 2 |
| 31 Mar 14 | 7 | -1 | 2 | 2 |
| 31 Dec 13 | 6 | 0 | 2 | 2 |
Kaliteli Kazançlar: ENDY is currently unprofitable.
Büyüyen Kar Marjı: ENDY is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: ENDY is unprofitable, and losses have increased over the past 5 years at a rate of 15.1% per year.
Büyüme Hızlandırma: Unable to compare ENDY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: ENDY is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-2.4%).
Özkaynak Getirisi
Yüksek ROE: ENDY has a negative Return on Equity (-5.69%), as it is currently unprofitable.